Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it will effect a one-for-ten reverse stock split of its common stock that will be effective on December 28, 2018.
December 24, 2018
· 4 min read